Journal
ONCOLOGY RESEARCH AND TREATMENT
Volume 40, Issue 5, Pages 294-297Publisher
KARGER
DOI: 10.1159/000464353
Keywords
PD1/PD-L1; Breast cancer; Immune checkpoints; Immunotherapy
Categories
Ask authors/readers for more resources
The programmed cell death-1 receptor (PD-1) is an immune checkpoint inhibitor which is expressed on the surface of immune effector cells. It is activated mainly by PD-L1 which can be expressed by all human cells. The PD-1/PD-L1 pathway plays a subtle role in maintaining peripheral T-lymphocyte tolerance and regulating inflammation. In cancer, the expression of PD-L1 seems to be one of the major immune escape mechanisms. Many studies have shown efficacy of blocking PD-1 or PD-L1 with specific antibodies like pembrolizumab or atezulizumab. In breast cancer, potential response was demonstrated in metastatic triple-negative breast cancers. (C) 2017 S. Karger GmbH, Freiburg
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available